Similarly, in breast cancer, the presence or absence of peripheral CD8+ T-cell responses to Her-2 peptides in vitro influences survival as shown in a cohort of elderly patients, whereas this was not the case for CD4+ T cell responses because these were present in almost all patients [23]. This evidence concerns the gene ERBB2 and breast carcinoma.